1. P.017 Optimization of acute treatment and headache-related impact following eptinezumab initiated during a migraine attack: post hoc analysis of the RELIEF study. (June 2022) Authors: Buse, DC; Lipton, RB; Ettrup, A; Josiassen, MK; Lindsten, A; Cady, R; Omeragic, A; Duong, A Journal: Canadian journal of neurological sciences Issue: Volume 49(2022)Supplement 1 Page Start: S12 Record Type: Journal Article View Content: Available online (eLD content is only available in our Reading Rooms) ↗
2. P.019 Interictal burden of migraine: correlations with other measures of migraine burden and effects of galcanezumab migraine-preventive treatment. (June 2022) Authors: Sandoe, CH; Lipton, RB; Buse, DC; Ford, JH; Hand, AL; Jedynak, JP; Port, MD; Detke, HC Journal: Canadian journal of neurological sciences Issue: Volume 49(2022)Supplement 1 Page Start: S12 Record Type: Journal Article View Content: Available online (eLD content is only available in our Reading Rooms) ↗